$XBI $64.91 | +3.34%
Table of Contents:
Covid Updates
$
Pipeline Updates
$MDWD +6% MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
$LVTX +0.5% LAVA THERAPEUTICS ANNOUNCES FDA IND CLEARANCE FOR LAVA-051 FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
$TARA 0% Protara Therapeutics Presents Results from Retrospective Analysis of Randomized and Open-Label Studies Evaluating the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations
$LPCN +0.3% Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
$NGM +8% NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
$RMTI -32% Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial
$CRBU +22% Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
$EDIT +8% Editas Medicine Receives FDA Orphan Drug Designation For EDIT-301 For The Treatment Of Beta Thalassemia
Business Updates
$CGEM +23% Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
$TCRX +2% TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting
$LTRN -8% Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month
$PRVB +6% Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year
$BBIO +14% bridgebio announces exclusive license agreement with bristol myers squibb to develop and commercialize bbp-398, a potentially best-in-class shp2 inhibitor, in oncology
$RMTI -32% Rockwell Medical Announces 1-for-11 Reverse Stock Split
$PCRX +2% PACIRA BIOSCIENCES REPORTS PRELIMINARY NET PRODUCT SALES FOR EXPAREL AND IOVERA° OF $45.8 MILLION FOR APRIL 2022
$HALO +1% Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
$PTN -1% Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock
$XERS -7% Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
$SIGA -3% Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
Posted by DV
Comments